2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Bernard J. Gersh; Barry J. Maron; Robert O. Bonow; Joseph A. Dearani; Michael A. Fifer; Mark S. Link; Srihari S. Naidu; Rick A. Nishimura; Steve R. Ommen; Harry Rakowski; Christine E. Seidman; Jeffrey A. Towbin; James E. Udelson; Clyde W. Yancy; Alice K. Jacobs; Sidney C. Smith; Jeffrey L. Anderson; Nancy M. Albert; Christopher E. Buller; Mark A. Creager; Steven M. Ettinger; Robert A. Guyton; Jonathan L. Halperin; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; E. Magnus Ohman; Richard L. Page; William G. Stevenson; Lynn G. Tarkington

doi:10.1016/j.jtcvs.2011.10.019

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Bernard J. Gersh^*, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy, Alice K. Jacobs, Sidney C. Smith, Jeffrey L. Anderson, Nancy M. Albert, Christopher E. Buller, Mark A. CreagerSteven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, E. Magnus Ohman, Richard L. Page, William G. Stevenson, Lynn G. Tarkington

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Original language	English (US)
Pages (from-to)	1303-1338
Number of pages	36
Journal	Journal of Thoracic and Cardiovascular Surgery
Volume	142
Issue number	6
DOIs	https://doi.org/10.1016/j.jtcvs.2011.10.019
State	Published - Dec 2011

Funding

The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of relationships with industry and other entities (RWI) among the writing committee. Specifically, all members of the writing committee, as well as peer reviewers of the document, are required to disclose all relevant relationships and those 12 months prior to initiation of the writing effort. The policies and procedures for RWI for this guideline were those in effect at the initial meeting of this committee (March 28, 2009), which included 50% of the writing committee with no relevant RWI. All guideline recommendations require a confidential vote by the writing committee and must be approved by a consensus of the members voting. Members who were recused from voting are indicated on the title page of this document with detailed information included in Appendix 1 . Members must recuse themselves from voting on any recommendations where their RWI apply. If a writing committee member develops a new RWI during his/her tenure, he/she is required to notify guideline staff in writing. These statements are reviewed by the Task Force and all members during each conference call and/or meeting of the writing committee and are updated as changes occur. For detailed information regarding guideline policies and procedures, please refer to the ACCF/AHA methodology and policies manual. 1 RWI pertinent to this guideline for authors and peer reviewers are disclosed in Appendixes 1 and 2 , respectively. Comprehensive disclosure information for the Task Force is also available online at http://www.cardiosource.org/ACC/About-ACC/Leadership/Guidelines-and-Documents-Task-Forces.aspx . The work of the writing committee was supported exclusively by the ACCF and AHA without commercial support. Writing committee members volunteered their time for this effort.

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jtcvs.2011.10.019

Cite this

Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., Seidman, C. E., Towbin, J. A., Udelson, J. E., Yancy, C. W., Jacobs, A. K., Smith, S. C., Anderson, J. L., Albert, N. M., Buller, C. E., ... Tarkington, L. G. (2011). 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 142(6), 1303-1338. https://doi.org/10.1016/j.jtcvs.2011.10.019

@article{58bb37849a00433d8d0aaf63957f16da,

title = "2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary",

author = "Gersh, {Bernard J.} and Maron, {Barry J.} and Bonow, {Robert O.} and Dearani, {Joseph A.} and Fifer, {Michael A.} and Link, {Mark S.} and Naidu, {Srihari S.} and Nishimura, {Rick A.} and Ommen, {Steve R.} and Harry Rakowski and Seidman, {Christine E.} and Towbin, {Jeffrey A.} and Udelson, {James E.} and Yancy, {Clyde W.} and Jacobs, {Alice K.} and Smith, {Sidney C.} and Anderson, {Jeffrey L.} and Albert, {Nancy M.} and Buller, {Christopher E.} and Creager, {Mark A.} and Ettinger, {Steven M.} and Guyton, {Robert A.} and Halperin, {Jonathan L.} and Hochman, {Judith S.} and Krumholz, {Harlan M.} and Kushner, {Frederick G.} and Ohman, {E. Magnus} and Page, {Richard L.} and Stevenson, {William G.} and Tarkington, {Lynn G.}",

note = "Funding Information: The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of relationships with industry and other entities (RWI) among the writing committee. Specifically, all members of the writing committee, as well as peer reviewers of the document, are required to disclose all relevant relationships and those 12 months prior to initiation of the writing effort. The policies and procedures for RWI for this guideline were those in effect at the initial meeting of this committee (March 28, 2009), which included 50% of the writing committee with no relevant RWI. All guideline recommendations require a confidential vote by the writing committee and must be approved by a consensus of the members voting. Members who were recused from voting are indicated on the title page of this document with detailed information included in Appendix 1 . Members must recuse themselves from voting on any recommendations where their RWI apply. If a writing committee member develops a new RWI during his/her tenure, he/she is required to notify guideline staff in writing. These statements are reviewed by the Task Force and all members during each conference call and/or meeting of the writing committee and are updated as changes occur. For detailed information regarding guideline policies and procedures, please refer to the ACCF/AHA methodology and policies manual. 1 RWI pertinent to this guideline for authors and peer reviewers are disclosed in Appendixes 1 and 2 , respectively. Comprehensive disclosure information for the Task Force is also available online at http://www.cardiosource.org/ACC/About-ACC/Leadership/Guidelines-and-Documents-Task-Forces.aspx . The work of the writing committee was supported exclusively by the ACCF and AHA without commercial support. Writing committee members volunteered their time for this effort. ",

year = "2011",

month = dec,

doi = "10.1016/j.jtcvs.2011.10.019",

language = "English (US)",

volume = "142",

pages = "1303--1338",

journal = "Journal of Thoracic and Cardiovascular Surgery",

issn = "0022-5223",

publisher = "Elsevier Inc.",

number = "6",

}

Gersh, BJ, Maron, BJ, Bonow, RO, Dearani, JA, Fifer, MA, Link, MS, Naidu, SS, Nishimura, RA, Ommen, SR, Rakowski, H, Seidman, CE, Towbin, JA, Udelson, JE, Yancy, CW, Jacobs, AK, Smith, SC, Anderson, JL, Albert, NM, Buller, CE, Creager, MA, Ettinger, SM, Guyton, RA, Halperin, JL, Hochman, JS, Krumholz, HM, Kushner, FG, Ohman, EM, Page, RL, Stevenson, WG & Tarkington, LG 2011, '2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary', Journal of Thoracic and Cardiovascular Surgery, vol. 142, no. 6, pp. 1303-1338. https://doi.org/10.1016/j.jtcvs.2011.10.019

TY - JOUR

T1 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy

T2 - Executive summary

AU - Gersh, Bernard J.

AU - Maron, Barry J.

AU - Bonow, Robert O.

AU - Dearani, Joseph A.

AU - Fifer, Michael A.

AU - Link, Mark S.

AU - Naidu, Srihari S.

AU - Nishimura, Rick A.

AU - Ommen, Steve R.

AU - Rakowski, Harry

AU - Seidman, Christine E.

AU - Towbin, Jeffrey A.

AU - Udelson, James E.

AU - Yancy, Clyde W.

AU - Jacobs, Alice K.

AU - Smith, Sidney C.

AU - Anderson, Jeffrey L.

AU - Albert, Nancy M.

AU - Buller, Christopher E.

AU - Creager, Mark A.

AU - Ettinger, Steven M.

AU - Guyton, Robert A.

AU - Halperin, Jonathan L.

AU - Hochman, Judith S.

AU - Krumholz, Harlan M.

AU - Kushner, Frederick G.

AU - Ohman, E. Magnus

AU - Page, Richard L.

AU - Stevenson, William G.

AU - Tarkington, Lynn G.

N1 - Funding Information: The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of relationships with industry and other entities (RWI) among the writing committee. Specifically, all members of the writing committee, as well as peer reviewers of the document, are required to disclose all relevant relationships and those 12 months prior to initiation of the writing effort. The policies and procedures for RWI for this guideline were those in effect at the initial meeting of this committee (March 28, 2009), which included 50% of the writing committee with no relevant RWI. All guideline recommendations require a confidential vote by the writing committee and must be approved by a consensus of the members voting. Members who were recused from voting are indicated on the title page of this document with detailed information included in Appendix 1 . Members must recuse themselves from voting on any recommendations where their RWI apply. If a writing committee member develops a new RWI during his/her tenure, he/she is required to notify guideline staff in writing. These statements are reviewed by the Task Force and all members during each conference call and/or meeting of the writing committee and are updated as changes occur. For detailed information regarding guideline policies and procedures, please refer to the ACCF/AHA methodology and policies manual. 1 RWI pertinent to this guideline for authors and peer reviewers are disclosed in Appendixes 1 and 2 , respectively. Comprehensive disclosure information for the Task Force is also available online at http://www.cardiosource.org/ACC/About-ACC/Leadership/Guidelines-and-Documents-Task-Forces.aspx . The work of the writing committee was supported exclusively by the ACCF and AHA without commercial support. Writing committee members volunteered their time for this effort.

PY - 2011/12

Y1 - 2011/12

UR - http://www.scopus.com/inward/record.url?scp=81255163417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255163417&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2011.10.019

DO - 10.1016/j.jtcvs.2011.10.019

M3 - Article

C2 - 22093712

AN - SCOPUS:81255163417

SN - 0022-5223

VL - 142

SP - 1303

EP - 1338

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

IS - 6

ER -

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this